Sorry, you need to enable JavaScript to visit this website.
Skip to main content
Home

Main navigation

  • Foundations of Science

    • Understanding Conditions
      • Autoimmune Diseases
      • Cancer
      • Cardiovascular & Metabolism
      • Rare Diseases
      • Infectious Diseases

    • Biology Basics
      • Genetics
      • Immune System

    • Science in the Everyday
  • Advancing Medical Research

    • Innovations
      • Drug Discovery
      • Clinical Trials
      • Our Scientists
      • Technology

    • Focus Areas
      • Covid-19
      • Immunology
      • Oncology
      • Vaccines
      • Cardiovascular & Metabolism
  • podcasts

Header top

  • About

Social

  • Facebook
  • Twitter
  • YouTube
  • Rss feed

Main navigation

  • Foundations of Science

    • Understanding Conditions
      • Autoimmune Diseases
      • Cancer
      • Cardiovascular & Metabolism
      • Rare Diseases
      • Infectious Diseases

    • Biology Basics
      • Genetics
      • Immune System

    • Science in the Everyday
  • Advancing Medical Research

    • Innovations
      • Drug Discovery
      • Clinical Trials
      • Our Scientists
      • Technology

    • Focus Areas
      • Covid-19
      • Immunology
      • Oncology
      • Vaccines
      • Cardiovascular & Metabolism
  • podcasts
Advancing Medical Research

Partnering to Turn the 'Undruggable' into Promising Targets

BY BREAKTHROUGHS STAFFDec 13, 2019

Partnering to Turn the 'Undruggable' into Promising Targets

Partnering to Turn the 'Undruggable' into Promising Targets

An image from a genetically engineered mouse model of lung cancer driven by the Kras gene. Scientists are studying the links between DUBS and historically undruggable targets. National Cancer Institute, National Institutes of Health

In the world of drug discovery, “undruggable” targets are like the stubborn children of biology, proteins that are considered too challenging to bind with conventional molecules. With the rapid pace of scientific advancement, however, the “undruggable” targets of yesterday now represent a promising new area of research.

Such is the case with deubiquitinating enzymes (DUBs), a family of some 100 proteins that play a role in regulating the right balance of proteins in cells. In 2017, academic researchers published breakthrough findings on this enzyme family, garnering interest in its potential to aid in treating cancer, as well as autoimmune, cardio-metabolic diseases.

The key to turning these cutting-edge insights into new medicines? Partnership.

Pfizer recently deepened its ongoing collaboration with Mission Therapeutics, a UK biotech company that researches medicines that target DUBs, enzymes which act as cellular waste disposal systems for toxic proteins. As a part of the partnership, Pfizer can access specific DUB inhibitors from Mission’s platform and test them as potential drug targets.

The recent announcement expands on Pfizer’s work in protein degradation: Last year, Pfizer formed the Innovative Target Exploration Network (ITEN), an early-stage collaboration model that includes leading institutions like Cambridge University, Oxford University, Imperial College and University College London in the United Kingdom. One of its key goals is to uncover critical findings about DUBs.

The ‘DUBs club’

“In order to be first-in-class with a drug, we’ve got to be first on the biology,” says Dafydd Owen, Director Medicinal Chemistry at Pfizer’s Cambridge, Massachusetts, research site. “It’s about interpreting academic innovation into timely programs.”

Recognizing that cross-disciplinary innovation starts within Pfizer, he added, scientists have created a “DUBs club”—a regular meeting of representatives from each of the research areas—to ensure that the collaborative studies are aligning with eventual therapeutic goals.

DUBs are the counterpoint to E3 ligases, which are enzymes involved in the ubiquitination process that tags proteins to be sent to the cellular “garbage disposal,” the proteasome.

As their name suggests, DUBS (deubiquitinating enzymes) counter the process of protein destruction by cleaving the ubiquitin unit from the protein it was tagging. This also allows the ubiquitin to be recycled and used elsewhere.

Scientists hypothesize that if DUBs are blocked or deleted, it can result in increased ubiquitination and removal of unwanted proteins.

Promising applications

Even though the science is still emerging, researchers are uncovering some promising therapeutic applications. DUBs have been shown to play a role in regulating protein levels such as p53, which is mutated in several types of cancers. Scientists are studying whether deleting certain DUBs has an overall effect on other such nodal proteins for oncology.

“If you found a DUB that was somehow controlling the abundance of these so-called undruggable targets, then drugging that DUB could be a way of tackling what’s driving the cancer,” says Owen.

We’re bringing together complementary, non-overlapping expertise so we can move forward to develop innovative therapies for patients

Linda Lohr

A breadth of science

The breadth of science represented by the ITEN collaboration means researchers could have even greater success discovering potential new biological targets and better research tools. For example, researchers are conducting functional genomic studies on DUBs and developing cell-based models to test these proteins with medicines. Another group is using predictive computational biology to better understand structure in the protein family. This opens the possibility of virtual screening for new DUBs therapeutic targets.

By tapping into the unique skill sets of their research partners, Pfizer scientists hope to find the therapeutic areas where their knowledge on DUBs can make the biggest impact. “We’re bringing together complementary, non-overlapping expertise so we can move forward to develop innovative therapies for patients,” says Linda Lohr, a member of Pfizer’s Emerging Science & Innovation group, focused on translating emerging science into Pfizer’s early stage portfolio.

 

Tags
Drug Discovery
Partnerships
Innovation
Read More
Blood Brain Barrier_Header.jpg
Seizing upon a ‘Special Sauce’ of Drug Development to Fight Cancer in the Brain
ViralMutations_Header.png
How Do Viruses Mutate and What it Means for a Vaccine?
1_v3_2000px.png
A Life-Saving Education: The Body’s Response to a Vaccine
Understanding Long-Haul COVID-19
Understanding Long-Haul COVID-19
Show
Hide

Get the Latest Updates

pfizer logo

Footer menu

  • About
  • Privacy Policy
  • Terms and Conditions
  • Contact Us

Social

  • Facebook
  • Twitter
  • YouTube
  • Rss feed

Copyright © 2002-2020 Pfizer Inc. All rights reserved. This information-including product information-is intended only for residents of the United States. The products discussed herein may have different labeling in different countries.